The agreement has an initial term until March 31, 2029 and no further details on the financial terms of the deal are being disclosed
This tie-up will have no impact on any other brands of the company
DSP-5336, an Investigational Menin and Mixed-lineage Leukemia Inhibitor, is Being Evaluated in Patients with Relapsed or Refractory Acute Leukemia
Investing in Malaysia's largest clinic operator to expand the healthcare business
The first and only oral androgen deprivation therapy treatment for men with advanced prostate cancer
Sharma joined the Morepen Lab in 2004
Connecting new production and consumption areas of chilled food by low-carbon transportation services
Through our research, we aim to ultimately provide new options for our customers to treat life-threatening infections in livestock
Subscribe To Our Newsletter & Stay Updated
